Yang, Z.; Suda, G.; Maehara, O.; Ohara, M.; Yoshida, S.; Hosoda, S.; Kimura, M.; Kubo, A.; Tokuchi, Y.; Fu, Q.;
et al. Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers 2022, 14, 232.
https://doi.org/10.3390/cancers14010232
AMA Style
Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Fu Q,
et al. Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2022; 14(1):232.
https://doi.org/10.3390/cancers14010232
Chicago/Turabian Style
Yang, Zijian, Goki Suda, Osamu Maehara, Masatsugu Ohara, Sonoe Yoshida, Shunichi Hosoda, Megumi Kimura, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu,
and et al. 2022. "Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma" Cancers 14, no. 1: 232.
https://doi.org/10.3390/cancers14010232
APA Style
Yang, Z., Suda, G., Maehara, O., Ohara, M., Yoshida, S., Hosoda, S., Kimura, M., Kubo, A., Tokuchi, Y., Fu, Q., Yamada, R., Kitagataya, T., Suzuki, K., Kawagishi, N., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K.,
... Sakamoto, N.
(2022). Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 14(1), 232.
https://doi.org/10.3390/cancers14010232